Results 201 to 210 of about 759,283 (267)

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Regulatory Readiness for Paper Replacement in Global Pharmaceutical Electronic Labeling: Cross-Sectional Comparative Policy Analysis. [PDF]

J Med Internet Res
Lee DE, Chun JS, Kim M, Kim IW, Oh JM.
europepmc   +1 more source

Association Between Motor Pathway Damage and Motor Deficit in Upper and Lower Limb in People With MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Corticospinal tract damage is common in people with MS, but the degree of clinical symptoms varies. We hypothesize that corticospinal tract lesions are more extensive and severe in people with MS with motor impairments in both upper and lower limbs.
Mathilde Liffran, Malo Gaubert, Alice Dufey, Elise Bannier, Audrey Rico, Jean‐Christophe Ferré, Raphaël Chouteau, Laure Michel, Emmanuelle Le Page, Virginie Callot, Bertrand Audoin, Sarah Demortière, Benoît Combès, Anne Kerbrat   +13 more
wiley   +1 more source

Spatial and Volumetric Characteristics of Glioblastoma: Associations With Clinical Presentation and Survival

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We aim to comprehensively analyze how regional tumor and edema characteristics are associated with clinical presentations and survival outcomes in a large cohort of glioblastoma patients. Methods Patients with IDH‐wildtype glioblastoma who received brain MRI from 2010 to 2023 were included.
Daniel J. Zhou, Marc Jaskir, Julian Gal, Yombe Fonkeu, Christos Davatzikos, MacLean P. Nasrallah, Jose Garcia, Rubo Xing, Stephen J. Bagley, Arati Desai, Richard E. Phillips, Steven Tobochnik, Colin A. Ellis, James J. Gugger, Nishant Sinha, Joel M. Stein, Kathryn A. Davis   +16 more
wiley   +1 more source

Current progress of labeling strategies in tissue clearing for large-scale biological visualization. [PDF]

Front Cell Dev Biol
Wang SW, Wang YQ, Deng JW, Yang SB, Wang FY, Wu J, Liu JG.   +6 more
europepmc   +1 more source

Metabolic RNA Labeling: Adding a Temporal Dimension to Transcriptomics and Epitranscriptomics Analysis. [PDF]

ACS Meas Sci Au
Wang D, Zhang Z, Lin S, Yang C.
europepmc   +1 more source

Understanding Postmarketing Requirements and Commitments for CYP3A-Mediated Drug-Drug Interactions: An Analysis of FDA-Approved Drugs From 2015 to 2024. [PDF]

Clin Transl Sci
Yu J, Petrie I, Argon S, Owens K, Ragueneau-Majlessi I.   +4 more
europepmc   +1 more source

Advancements and applications of click chemistry in protein labeling and bioconjugation. [PDF]

RSC Adv
Nazeer U, Qin G, Cai C.
europepmc   +1 more source

Towards reliable tracking of natural killer cells using commercial iron oxide nanoparticles and magnetic particle imaging.

Biomater Sci
Lightsey S, Consalvo V, Ali SR, Valdés DP, Oyer JL, Gloger G, Copik AJ, Rinaldi-Ramos C, Sharma B.   +8 more
europepmc   +1 more source